Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
43.72
-0.06 (-0.14%)
At close: Aug 14, 2026, 4:00 PM EDT
43.83
+0.11 (0.25%)
After-hours: Aug 14, 2026, 7:30 PM EDT
Sanofi Employees
Sanofi had 74,846 employees as of December 31, 2025. The number of employees decreased by 8,032 or -9.69% compared to the previous year.
Employees
74,846
Change (1Y)
-8,032
Growth (1Y)
-9.69%
Revenue / Employee
$746,710
Profits / Employee
$60,416
Market Cap
104.76B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 74,846 | -8,032 | -9.69% |
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
| Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
| Dec 31, 2017 | 106,566 | -293 | -0.27% |
| Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
| Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
| Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
| Dec 31, 2013 | 112,128 | 154 | 0.14% |
| Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
| Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
| Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
| Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
| Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
| Dec 31, 2007 | 99,495 | -794 | -0.79% |
| Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
| Dec 31, 2005 | 97,181 | 742 | 0.77% |
| Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
| Dec 31, 2003 | 33,086 | 650 | 2.00% |
| Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
| Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
| Dec 31, 2000 | 29,200 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
| Bristol-Myers Squibb Company | 32,500 |
SNY News
- 4 days ago - Sanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley - TheFly
- 5 days ago - Sanofi facing shortages of two drugs for Pompe disease, STAT reports - TheFly
- 8 days ago - Novavax Q2 Earnings Call Highlights - Nasdaq
- 11 days ago - Sanofi's MenQuadfi Wins EC Approval For Use In Six Week Old Infants Against Meningococcal Disease - Nasdaq
- 11 days ago - Sanofi: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease - Finanz Nachrichten
- 11 days ago - Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease - GlobeNewsWire
- 15 days ago - Sanofi SA (SNY) Stock Down 4.5% -- Now Undervalued? GF Score: 70/100 - GuruFocus
- 16 days ago - Sanofi (SNY) Faces Stock Decline Amid CEO's Warning on Drug Pipeline Challenges - GuruFocus